Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.58 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638348 | 0.87 | TGFBR1 (0.61) | TGFBR1DYRK1AGRM2 | |
| SCHEMBL15640113 | 0.85 | TGFBR1 (0.55) | TGFBR1PIM1DYRK1A | |
| SCHEMBL15639969 | 0.85 | TGFBR1 (0.60) | TGFBR1TGFBR2DYRK1A | |
| SCHEMBL15638144 | 0.84 | TGFBR1 (0.59) | TGFBR1TGFBR2DYRK1APDE4APDE3A | |
| SCHEMBL15638648 | 0.81 | TGFBR1 (0.65) | TGFBR1TGFBR2DYRK1APDE4APDE3A | |
| SCHEMBL15640130 | 0.81 | TGFBR1 (0.46) | TGFBR1TGFBR2PIM1SRCGSK3A | |
| SCHEMBL15849392 | 0.81 | TGFBR1 (0.49) | TGFBR1TGFBR2PIM1SRCGSK3A | |
| SCHEMBL15638107 | 0.80 | TGFBR1 (0.64) | TGFBR1DYRK1AGRM2 | |
| SCHEMBL15730182 | 0.79 | TGFBR1 (0.64) | TGFBR1TGFBR2DYRK1APDE4APDE3A | |
| SCHEMBL24716444 | 0.79 | TGFBR1 (0.59) | TGFBR1TGFBR2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TGFBR1 128/4885TGFBR2 112/4885PIM1 3017/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TGFBR1 128/4885TGFBR2 112/4885PIM1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.